| Survival: | 9.4 months |
| Toxicity Grade: | 4 |
| Treatments: | Chemotherapy |
| Drugs: | Gemzar Platinol |
| Country: | Netherlands |
| City/State/Province: | Rotterdam |
| Hospital: | University Hospital Rotterdam |
| Journal: | Link |
| Date: | 2/2002 |
| Description: |
| Patients: This Phase II trial involved 32 patients with malignant pleural mesothelioma. None of these patients had received prior chemotherapy. Treatment: The treatment consisted of two chemotherapy drugs, gemcitabine (gemzar) and cisplatin (platinol). Toxicity: Grade 4 toxicities included nausea and vomiting. Grade 3 toxicities included hematologic, nausea and vomiting, fatigue anorexia, diarrhea, neurotoxicity, cardiovascular. Results: The median survival from the start of treatment was 9.4 months. Support: This study was supported in part by Lilly BV. Lilly markets gemzar. Correspondence: JP van Meerbeeck, MD |